Literature DB >> 22037168

The roles of activin A and its binding protein, follistatin, in inflammation and tissue repair.

David M de Kretser1, Robyn E O'Hehir, Charles L Hardy, Mark P Hedger.   

Abstract

Activin A, a member of the transforming growth factor-β superfamily of cytokines, is a critical controller of inflammation, immunity and fibrosis. It is rapidly released into the blood following a lipopolysaccharide challenge in experimental animals, through activation of the Toll-like receptor 4 signalling pathway. Blocking activin action by pre-treatment with its binding protein, follistatin, modifies the inflammatory cytokine cascade, and reduces the severity of the subsequent inflammatory response and mortality. Likewise, high serum levels of activin A are predictive of death in patients with septicaemia. However, activin A has complex immunomodulatory actions. It is produced by inflammatory macrophages, but can regulate either pro- or anti-inflammatory responses in these cells, depending on their prior activation status. Activin A is also produced by Th2 cells, and stimulates antibody production by B cells and the development of regulatory T cells. Production of activin A during inflammatory responses stimulates fibrosis and tissue remodelling, and follistatin inhibits these actions of activin A. The modulation of activin by follistatin may represent an important therapeutic target for the modulation and amelioration of inflammatory and fibrotic disorders.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22037168     DOI: 10.1016/j.mce.2011.10.009

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  59 in total

1.  Loss of BMPR2 leads to high bone mass due to increased osteoblast activity.

Authors:  Jonathan W Lowery; Giuseppe Intini; Laura Gamer; Sutada Lotinun; Valerie S Salazar; Satoshi Ote; Karen Cox; Roland Baron; Vicki Rosen
Journal:  J Cell Sci       Date:  2015-02-06       Impact factor: 5.285

2.  Activin A expression in esophageal carcinoma and its association with tumor aggressiveness and differentiation.

Authors:  Zhenhua Wang; Ning Zhang; Ruifeng Song; Ruitai Fan; Liuqin Yang; Liping Wu
Journal:  Oncol Lett       Date:  2015-05-20       Impact factor: 2.967

3.  Identification and characterization of a novel heparan sulfate-binding domain in Activin A longest variants and implications for function.

Authors:  Evan Yang; Christina Mundy; Eric F Rappaport; Maurizio Pacifici; Paul C Billings
Journal:  PLoS One       Date:  2019-09-19       Impact factor: 3.240

4.  Targeted Analysis of Three Hormonal Systems Identifies Molecules Associated with the Presence and Severity of NAFLD.

Authors:  Stergios A Polyzos; Nikolaos Perakakis; Chrysoula Boutari; Jannis Kountouras; Wael Ghaly; Athanasios D Anastasilakis; Asterios Karagiannis; Christos S Mantzoros
Journal:  J Clin Endocrinol Metab       Date:  2020-03-01       Impact factor: 5.958

5.  Circulating angiogenic factors associated with response and survival in patients with acute graft-versus-host disease: results from Blood and Marrow Transplant Clinical Trials Network 0302 and 0802.

Authors:  Shernan G Holtan; Michael R Verneris; Kirk R Schultz; Laura F Newell; Gabrielle Meyers; Fiona He; Todd E DeFor; Gregory M Vercellotti; Arne Slungaard; Margaret L MacMillan; Sarah A Cooley; Bruce R Blazar; Angela Panoskaltsis-Mortari; Daniel J Weisdorf
Journal:  Biol Blood Marrow Transplant       Date:  2015-03-07       Impact factor: 5.742

6.  Intravascular innate immune cells reprogrammed via intravenous nanoparticles to promote functional recovery after spinal cord injury.

Authors:  Jonghyuck Park; Yining Zhang; Eiji Saito; Steve J Gurczynski; Bethany B Moore; Brian J Cummings; Aileen J Anderson; Lonnie D Shea
Journal:  Proc Natl Acad Sci U S A       Date:  2019-07-08       Impact factor: 11.205

7.  Imbalance of Amniotic Fluid Activin-A and Follistatin in Intraamniotic Infection, Inflammation, and Preterm Birth.

Authors:  John T Hardy; Irina A Buhimschi; Megan E McCarthy; Guomao Zhao; Christine A Laky; Lydia L Shook; Catalin S Buhimschi
Journal:  J Clin Endocrinol Metab       Date:  2016-05-09       Impact factor: 5.958

8.  Transforming Growth Factor-β Family Ligands Can Function as Antagonists by Competing for Type II Receptor Binding.

Authors:  Senem Aykul; Erik Martinez-Hackert
Journal:  J Biol Chem       Date:  2016-03-09       Impact factor: 5.157

9.  The nutrigenomic investigation of C57BL/6N mice fed a short-term high-fat diet highlights early changes in clock genes expression.

Authors:  Michela Lizier; Lorenzo Bomba; Andrea Minuti; Fatima Chegdani; Jessica Capraro; Barbara Tondelli; Raffaele Mazza; Maria Luisa Callegari; Erminio Trevisi; Filippo Rossi; Paolo Ajmone Marsan; Franco Lucchini
Journal:  Genes Nutr       Date:  2013-04-16       Impact factor: 5.523

10.  Late acute graft-versus-host disease: a prospective analysis of clinical outcomes and circulating angiogenic factors.

Authors:  Shernan G Holtan; Nandita Khera; John E Levine; Xiaoyu Chai; Barry Storer; Hien D Liu; Yoshihiro Inamoto; George L Chen; Sebastian Mayer; Mukta Arora; Jeanne Palmer; Mary E D Flowers; Corey S Cutler; Alexander Lukez; Sally Arai; Aleksandr Lazaryan; Laura F Newell; Christa Krupski; Madan H Jagasia; Iskra Pusic; William Wood; Anne S Renteria; Gregory Yanik; William J Hogan; Elizabeth Hexner; Francis Ayuk; Ernst Holler; Phandee Watanaboonyongcharoen; Yvonne A Efebera; James L M Ferrara; Angela Panoskaltsis-Mortari; Daniel Weisdorf; Stephanie J Lee; Joseph Pidala
Journal:  Blood       Date:  2016-09-13       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.